ReviewAntibiotics (Basel, Switzerland)2024
Comprehensive Approaches to Combatting
Review in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review
- Synthesis and In Vitro Biological Evaluation of Amphiphilic Derivatives of Carvacrol as Potent Antibacterial Agents.Antibiotics (Basel, Switzerland) · 2026Article
- An optimized CRISPR/Cas9-based genome editing platform enhances bacteriocin production in Lactiplantibacillus plantarum.Journal of biological engineering · 2026Article
- Protecting Newborns from Multidrug-Resistant Infections: The Emerging Role of Bacteriophages.Viruses · 2026Review
- Mapping the global landscape of biofilm-associated antimicrobial resistance (1992-2025).Biofilm · 2026Article
- Synergistic Inhibition ofMicroorganisms · 2026Article
- AUBFM01 Phage as a Therapeutic Candidate Against MDRMicroorganisms · 2026Article
- Isolation, characterization and genomic insights of the lytic bacteriophage TANUVAS_MVC-VPH-AB targeting Acinetobacter spp. with antibacterial and anti-biofilm activity.Molecular biology reports · 2026Article
- Antibiofilm activity of a chionodracine-derived peptide by NMR-based metabolomics of cell-free supernatant of Acinetobacter baumannii clinical strains.FEBS open bio · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Advancing climate-resilient livestock systems: Next-generation emission mitigation strategies and integrated technological innovations.Veterinary and animal science · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Article
- Advances in phage therapy forFrontiers in microbiology · 2026Review
- Phage enabled precision drug delivery: dual function platforms for therapeutics and genetic cargo transport.Frontiers in microbiology · 2026Review
- Identification, resistance mechanisms, and innovative therapeutic approaches againstFrontiers in microbiology · 2026Review
- Genomic and phenotypic insights into broad-spectrum antiVeterinary world · 2025Article
- Fighting biofilm: bacteriophages eliminate biofilm formed by multidrug-resistant Enterobacter hormaechei on urological catheters.Medical microbiology and immunology · 2025Article
- Isolation and Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.